Device-Activated Drugs, An Old Dog With Some New Tricks
As technologies move from the lab to commercialization, changes to them need to be made to make them financially and practically appropriate for clinical settings. Medtech Insight spoke to two companies pioneering new types of device-activated drugs to learn about these changes and how the end products will help patients.
You may also be interested in...
Medtech Insight's Approvals Tracker reports 22 medical device approvals from outside the United States in November, including 12 CE marks from Europe, plus approvals from Taiwan, Singapore, Japan, India, Canada, Australia and Argentina.
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb provides highlights from the recent HLTH conference in Las Vegas. Reed Miller and Barnaby Pickering offer an overview of the highly competitive diabetes tech market. We also talk about digital health in Germany and Europe.
CMR Surgical has grown rapidly since being founded just over eight years ago. However, unlike most other medtech companies, CMR is not selling a ~$30 diagnostic test, or a ~$5,000 pacemaker. It is selling a complex surgical robot, called Versius, with a price tag rumored to be in the seven figures.